Abstract:Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Crizotinib, a first ever ALK /MET multi-targeted receptor tyrosine kinase inhibitor developed by Pfizer and fast approved by FDA in 2011 for the treatment of ALK-rearranged NSCLC patients. We hypothesize that crizotinib acts on other molecular targets in addition to tyrosine kinases ALK/MET and may play critical role given that there is a complex network of kinases that work together to regulate a number of important cellular processes and different disease signature. Approaching with a comprehensive docking method with our established chemical-protein interactome (CPI) and crizotinib, we have discovered 301 PDB-deposited proteins corresponding to 353 ligand binding pockets among a total of 1,780 PDB-deposited human protein entries. Systemic pharmacology approach also applied including validation the molecular target(s) of TKIs in vitro. Especially multiple human cellular models (including NSCLC and melanoma) and signaling study, luc-reporter, autophagy, apoptosis assay, FACS and NGS analysis applied. Interestingly, crizotinib besides had a high CPI binding score (ZZ_score) of -2.2778 against tyrosine kinase Lck, also had -1.4672, -1.1242, -0.7033 and -1.5384 against MAPK3, S6K, GSK-3β and HDAC 7A, respectively, which indicated crizotinib had potential broad range interaction with both TK and ser/thr kinases. In addition, those crizotinib achieved high ZZ scores against PPAR-γ (-1.6145) and VitD3R (0.9479), suggesting a high binding affinity of crizotinib with these nuclear proteins. Our preliminary studies have showed that the crizotinib induced autophagy by activated LC3 in vitro and inhibited oncogenic Akt/mTOR signaling in human multiple melanoma cells resulting in G2/M cell cycle arrest. Furthermore, crizotinib increased p21Waf1/cip1 and Foxo3A expression and tumor suppressor miR-146a in human melanoma cells. Taken together, crizotinib induces miR-146a, autophagy and p21 waf1/cip1 may potentially treat other type of human cancer by concurrently targeting tyrosine kinase, Akt/mTOR/Foxo axis and nuclear receptor, shedding a light for future both anti-cancer and anti-metabolic disorder drug discovery and development. This is the first CPI-based systemic study on leading discovery of crizotinib off-target phenotypic importance. These findings suggest that non-tyrosine kinase target of crizotinib may play critical role(s) for drug repositioning may represent a new and effective approach to expanding the application of existing drugs. Citation Format: Jiazhi Sun, Lun Yang, Minghua Li, Ian E. Heller, Issac Raplee, Steven Guzman, John P. Pasciak, Feng Cheng, Kevin B. Sneed, Lin He, Shu-Feng Zhou. Crizotinib induces tumor suppressor miR-146a, autophagy and p21 waf1/cip1 by alternative targeting non-TK target Akt-mTOR-Foxo axis: A CPI-based systemic study on discovery of phenotypic off-target. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3738. doi:10.1158/1538-7445.AM2014-3738

Crizotinib Induces Autophagy Through Inhibition of the Stat3 Pathway in Multiple Lung Cancer Cell Lines

Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.

Crizotinib induces pulmonary toxicity by blocking autophagy flux in alveolar epithelial cells

Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death

Crizotinib induces apoptosis of lung cancer cells through JAK-STAT pathway

Essential Role for STAT3/FOXM1/ATG7 Signaling-Dependent Autophagy in Resistance to Icotinib

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion

Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway

Autophagy Inhibition Promotes 5-Fluorouraci-induced Apoptosis by Stimulating ROS Formation in Human Non-Small Cell Lung Cancer A549 Cells.

EGFR Tyrosine Kinase Inhibitors Activate Autophagy As a Cytoprotective Response in Human Lung Cancer Cells

Cinchonine Exerts Anti-Tumor and Immunotherapy Sensitizing Effects in Lung Cancer by Impairing Autophagic-Lysosomal Degradation

Crizotinib-induced Immunogenic Cell Death in Non-Small Cell Lung Cancer

Overcoming Chemoresistance in Cancer: The Promise of Crizotinib

Induction of Autophagy by an Oleanolic Acid Derivative, SZC017, Promotes ROS‐dependent Apoptosis Through Akt and JAK2/STAT3 Signaling Pathway in Human Lung Cancer Cells

Crizotinib enhances PARP inhibitor efficacy in ovarian cancer cells and xenograft models by inducing autophagy

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells

Protective Autophagy Decreases Osimertinib Cytotoxicity Through Regulation of Stem Cell-Like Properties in Lung Cancer

Blocking Autophagy Improves the Anti-Tumor Activity of Afatinib in Lung Adenocarcinoma with Activating EGFR Mutations in Vitro and in Vivo

Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer

Abstract 3738: Crizotinib Induces Tumor Suppressor Mir-146A, Autophagy and P21 Waf1/cip1 by Alternative Targeting Non-Tk Target Akt-mTOR-Foxo Axis: A CPI-based Systemic Study on Discovery of Phenotypic Off-Target